…
ALR Technologies SG Ltd., a data management company, provides diabetes care management solutions. It offers ALRT Diabetes Solution, a diabetes care that includes a diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The company also provides GluCurve Pet CGM, a solution to address an unmet need in diabetes care for felines and canines by combining the hardware of a CGM with the software of an adapted version of diabetes solution product for use by veterinarians in animal health. In addition, it offers healthcare services, including medical clinics, hospitals, and health plans, and veterinary clinics with diabetics being the initial patient targets. The company sells its products directly and through distributors in the United States, Brazil, the United Kingdom, European Union, and internationally. The company was incorporated in 1987 and is based in Singapore.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on ALR Technologies Inc. (ALRTF) is limited and its core business activities and long-term growth drivers are not clearly documented in accessible filings or on a company website. Investors may be attracted by potential upside common to thinly traded PINK-listed issuers, but should monitor company disclosures and operational updates for substantiation.
Primary investment risks include limited disclosure and financial transparency, low liquidity, and elevated execution and financing risk typical of OTC Pink-listed microcap companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -22.06M | -15.88M | -7.48M | -10.62M | -8.44M |
| Net income | -22.06M | -15.88M | -7.47M | -10.62M | -8.44M |
| Selling general administrative | 2.09M | 2.62M | 3.37M | 3.73M | 5.84M |
| Gross profit | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Ebit | - | - | - | - | -2.94M |
| Ebitda | - | - | - | - | -6.40M |
| Operating income | -2.88M | -3.50M | -4.77M | -4.21M | -6.33M |
| Interest expense | 19.74M | 12.42M | 2.52M | 6.35M | 2.04M |
| Net interest income | -19.74M | -12.42M | -2.52M | -6.35M | -2.04M |
| Total revenue | 0.00M | 0.00M | 0.03M | 0.00M | 0.01M |
| Total operating expenses | 2.88M | 3.50M | 4.80M | 4.21M | 6.34M |
| Cost of revenue | 0.00M | 0.00M | 0.02M | 0.00M | 0.00M |
| Total other income expense net | 0.56M | 0.05M | -0.18M | -0.06M | -0.07M |
| Net income from continuing ops | -22.06M | -15.88M | -7.48M | -10.62M | -8.44M |
| Net income applicable to common shares | - | - | - | - | -8.44M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.05M | 0.08M | 0.16M | 0.38M | 0.19M |
| Total liab | 39.91M | 36.30M | 32.07M | 28.93M | 24.51M |
| Total stockholder equity | -39.86M | -36.22M | -31.92M | -28.55M | -24.31M |
| Other current liab | - | - | - | - | 0.00M |
| Common stock | - | - | - | - | 0.54M |
| Capital stock | 31.49M | 31.29M | 30.91M | 28.04M | 0.54M |
| Retained earnings | -158.04M | -135.99M | -120.11M | -112.63M | -102.02M |
| Cash | 0.02M | 0.04M | 0.06M | 0.15M | 0.12M |
| Total current liabilities | 39.91M | 36.30M | 32.07M | 27.09M | 24.51M |
| Net debt | 32.26M | 28.58M | 25.34M | 22.78M | 19.15M |
| Short long term debt | 32.28M | 28.62M | 25.40M | 21.08M | 19.26M |
| Other stockholder equity | - | - | - | - | -0.01M |
| Total current assets | 0.05M | 0.08M | 0.16M | 0.38M | 0.19M |
| Net tangible assets | - | - | - | - | -24.31M |
| Net receivables | - | 0.00M | 0.04M | 0.00M | - |
| Long term debt | - | - | - | 1.84M | - |
| Inventory | 0.01M | 0.01M | 0.01M | 0.00M | - |
| Accounts payable | 1.29M | 1.68M | 1.18M | 1.05M | 0.81M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | - | 0.21M |
| Net borrowings | 1.85M | 1.52M | 0.79M | 2.51M | 0.69M |
| Total cash from financing activities | 1.85M | 1.52M | 1.54M | 2.51M | 1.83M |
| Change to operating activities | - | - | - | - | 0.51M |
| Net income | -22.06M | -15.88M | -7.47M | -10.62M | -8.44M |
| Change in cash | -0.02M | -0.02M | -0.09M | 0.03M | 0.05M |
| Begin period cash flow | 0.04M | 0.06M | 0.15M | 0.12M | 0.07M |
| End period cash flow | 0.02M | 0.04M | 0.06M | 0.15M | 0.12M |
| Total cash from operating activities | -1.87M | -1.54M | -1.62M | -2.57M | -1.77M |
| Issuance of capital stock | 0.00M | 0.00M | 0.74M | 0.00M | 1.14M |
| Dividends paid | - | - | - | 0.00M | 0.00M |
| Change to inventory | 0.00M | 0.00M | -0.01M | 0.00M | - |
| Change to account receivables | 0.00M | 0.00M | -0.04M | 0.00M | - |
| Change to netincome | - | - | - | - | 5.95M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.88M | 1.03M | 1.13M | 0.73M | 0.72M |
| Stock based compensation | 18.27M | 11.53M | 2.87M | 5.77M | 4.40M |
| Other non cash items | 1.10M | 2.07M | 1.99M | 2.04M | 1.51M |
| Free cash flow | -1.87M | -1.54M | -1.62M | -2.57M | -1.77M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALRTF ALR Technologies Inc. |
0.00 10.71% |
0.02 | - | 29.67 | 364.05 | - | 1388.64 | -6.88 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
ALR Technologies SG Ltd., a data management company, provides diabetes care management solutions. It offers ALRT Diabetes Solution, a diabetes care that includes a diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The company also provides GluCurve Pet CGM, a solution to address an unmet need in diabetes care for felines and canines by combining the hardware of a CGM with the software of an adapted version of diabetes solution product for use by veterinarians in animal health. In addition, it offers healthcare services, including medical clinics, hospitals, and health plans, and veterinary clinics with diabetics being the initial patient targets. The company sells its products directly and through distributors in the United States, Brazil, the United Kingdom, European Union, and internationally. The company was incorporated in 1987 and is based in Singapore.
| Name | Title | Year Born |
|---|---|---|
| Mr. Sidney S. Chan | Chairman, CEO, CFO, Principal Accounting Officer, Treasurer & Sec. | 1950 |
| Mr. Steven Brassard C.A., CPA, CA, CPA | Director of Fin., Accounting & Admin. | 1986 |
| Ms. Jacqueline Wu | Head of Corp. Marketing | NA |
| Mr. Joe Stern | Head of Animal Health | NA |
| Dr. James R. Raphael Gavin III, M.D., Ph.D. | Sr. Medical Consultant | 1946 |
| Ms. Barbara Dubiel | Consultant | NA |
| Mr. Barrett D. Ehrlich | Consultant | NA |
| Mr. Mark Geoffrey Uy | Consultant | NA |
| Mr. Johnny Tlardera | Consultant | NA |
| Mr. John Lester Tolentino | Consultant | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.